Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6662447

C[C@@H](N)C(=O)OCCCCCNc1cccc2c1C(=O)c1ccccc1C2=O.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.47
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
ALDH1A1 P00352 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
POLB P06746 3/20 0.47
MAPK1 P28482 3/20 0.47
LMNA P02545 3/20 0.47
BLM P54132 2/20 0.47
EGFR P00533 2/20 0.47
HTT P42858 2/20 0.47
RAD52 P43351 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
RECQL P46063 1/20 0.47
TERT O14746 1/20 0.43
NSD2 O96028 2/20 0.42
FGB P02675 1/20 0.42
MMP14 P50281 1/20 0.42
MAOA P21397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6660806 1.00 MAPT (0.47) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6664129 0.99 MAPT (0.47) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6663851 0.99 MAPT (0.47) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6662414 0.97 MAPT (0.49) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6660175 0.97 MAPT (0.49) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6657746 0.92 MAPT (0.45) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6660230 0.92 MAPT (0.45) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6657753 0.92 MAPT (0.45) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6664776 0.89 MAPT (0.46) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6663121 0.89 MAPT (0.47) MAPTMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1087935-B1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INT LTD (GB) 2004-08-18 EP disclosed
US-20030203975-A1 Anti-cancer agents BTG INTERNATIONAL LIMITED (GB) 2003-10-30 US disclosed
EP-1087935-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 2001-04-04 EP disclosed
WO-1999065866-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203975-A1 Anti-cancer agents TOP2B, TOP2A, TOP1 MAPT 4879/4885MEN1 3787/4885KMT2A 3724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.